No connection

Search Results

INUV

BEARISH
$1.9 Live
Inuvo, Inc. · AMEX
Target $5.29 (+178.4%)
$1.62 52W Range $6.27
Overview AI Snowflake Price Valuation Profitability Growth Health Statements Peers Insiders SEC Filings

At a glance

Key valuation, profitability, growth, and risk metrics.

Updated Apr 29, 2026
Market cap
$27.96M
P/E
N/A
ROE
-43.4%
Profit margin
-5.9%
Debt/Equity
0.4
Dividend yield
N/A

AI Analysis

AI-powered fundamental assessment

Confidence
90%
INUV exhibits severe financial distress, highlighted by a Piotroski F-Score of 1/9, indicating critical weakness across nearly all fundamental health dimensions. The company is facing a revenue crisis with YoY and Q/Q growth plummeting by over 45%, coupled with a liquidity risk evidenced by a Current Ratio of 0.65. While gross margins remain strong at 74.49% and analysts maintain a high target price of $5.29, the combination of negative ROE (-43.37%) and a 0/100 technical trend suggests a high probability of further decline.

Key Strengths

Strong Gross Margin (74.49%)
Low Price-to-Sales ratio (0.32)
Manageable Debt/Equity ratio (0.40)
Consistent history of beating low EPS estimates
Significant gap between current price and analyst target price

Key Risks

Severe revenue contraction (-45.60% YoY)
Liquidity crisis with Current Ratio (0.65) and Quick Ratio (0.61) well below 1.0
Extreme negative long-term price performance (-77.9% over 5 years)
Negative Return on Equity (-43.37%) and Return on Assets (-14.67%)
Complete lack of technical momentum (Technical Trend: 0/100)

Performance Snowflake

Multi-dimensional analysis across 5 key categories

Overall
15
Weak
Value
40
Future
10
Past
15
Health
10
Dividend
0
AI Verdict
High Risk / Speculative
Key drivers: Revenue collapse, Critical Piotroski score, Liquidity shortfall, Bearish technicals
Confidence
85%
Value
40/100

Graham Number is N/A due to lack of positive earnings.

Positives
  • Very low P/S ratio (0.32)
Watchpoints
  • Negative earnings (P/E N/A)
  • Price/Book at 2.79 is high for a distressed asset
Future
10/100

Growth metrics are in a state of collapse.

Positives
  • Positive EPS surprises in recent quarters
Watchpoints
  • Revenue growth is deeply negative (-45.6%)
  • Forward P/E is -190.00
Past
15/100

Long-term trend is aggressively bearish.

Positives
  • Ability to maintain high gross margins
Watchpoints
  • 5-year price change of -77.9%
  • Consistent history of negative earnings
Health
10/100

F-Score indicates extreme financial fragility.

Positives
  • Debt/Equity is relatively low (0.40)
Watchpoints
  • Piotroski F-Score of 1/9
  • Current Ratio < 1.0
Dividend
0/100

Non-dividend paying growth/distressed stock.

Positives
No standout positives identified.
Watchpoints
  • No dividend payments
  • 0/100 dividend strength

Stock Price & Analyst Targets

Real-time price movements and analyst price targets

Current Price
$1.9
Analyst Target
$5.29
Upside/Downside
+178.4%

Multi-Horizon Performance vs Peers

Price momentum across 5Y → 1W horizons for INUV and closest competitors.

Updated 2026-04-28
INU
Inuvo, Inc.
Primary
5Y
-77.9%
3Y
-34.5%
1Y
-51.3%
6M
-33.8%
1M
+0.5%
1W
-7.8%
MOB
Mobix Labs, Inc.
Peer
5Y
-97.3%
3Y
-97.6%
1Y
-66.0%
6M
-69.3%
1M
-53.9%
1W
-21.5%
BOS
B.O.S. Better Online Solutions Ltd.
Peer
5Y
+23.3%
3Y
+74.0%
1Y
+21.0%
6M
-4.0%
1M
-3.1%
1W
-10.3%
MAX
Maxeon Solar Technologies, Ltd.
Peer
5Y
-99.9%
3Y
-100.0%
1Y
-44.4%
6M
-55.2%
1M
-31.2%
1W
-7.0%
ORI
Orion Digital Corp.
Peer
5Y
-95.4%
3Y
-48.1%
1Y
+31.3%
6M
-41.1%
1M
+4.8%
1W
+3.8%

Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.

Historical Performance Trends

Long-term financial metrics and growth patterns

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Historical data shows last 12 quarters (3 years)

Valuation Metrics

Key valuation ratios and pricing indicators

P/E Ratio
N/A
Forward P/E
-190.0
PEG Ratio
0.31
P/B Ratio
2.79
P/S Ratio
0.32
EV/Revenue
0.34
EV/EBITDA
-6.56
Market Cap
$27.96M

Profitability

Profit margins and return metrics

Profit Margin -5.91%
Operating Margin -8.51%
Gross Margin 74.49%
ROE -43.37%
ROA -14.67%

Growth

Revenue and earnings growth rates

Revenue Growth -45.6%
Earnings Growth N/A
Q/Q Revenue Growth -45.55%
Q/Q Earnings Growth N/A

Financial Health

Balance sheet strength and liquidity metrics

Debt/Equity
0.4
Low debt
Current Ratio
0.65
Weak
Quick Ratio
0.61
Poor
Cash/Share
$0.19

Financial Statement Flow

Interactive flow visualization showing how money moves through the company Q4 2025

Revenue
$0.0B
Gross Margin
66.4%
Op. Margin
-8.5%
Net Margin
-4.2%
Total Assets
$0.0B
Liabilities
$0.0B
Equity
$0.0B
Debt/Equity
1.48x
Operating CF
$0.0B
CapEx
$-0.0B
Free Cash Flow
$-0.0B
FCF Yield
-1618%

Quarterly Earnings History

EPS performance vs analyst estimates

2026-05-15
$N/A
2026-03-05
$-0.04
+87.3% surprise
2025-11-06
$-0.12
-50.0% surprise
2025-08-07
$-0.1
+21.6% surprise

Technology Sector Comparison

Comparing INUV against 578 companies in the Technology sector (44 bullish, 207 neutral, 327 bearish)
Return on Equity (ROE)
-43.37%
This Stock
vs
-32.59%
Sector Avg
+33.1% (Excellent)
Profit Margin
-5.91%
This Stock
vs
-11.64%
Sector Avg
-49.2% (Weaker)
Debt to Equity
0.4
This Stock
vs
0.77
Sector Avg
-47.5% (Less Debt)
Revenue Growth
-45.6%
This Stock
vs
4282.83%
Sector Avg
-101.1% (Slower)
Current Ratio
0.65
This Stock
vs
3.6
Sector Avg
-82.1% (Weaker)

Similar Companies

Peer comparison within the same industry

INUV Inuvo, Inc.
BEARISH
Mkt Cap
$28M
P/E
-
ROE
-43.4%
Price
$1.9
MOBX Mobix Labs, Inc.
BEARISH
Mkt Cap
$28M
P/E
-
ROE
-4473.8%
Price
$2.63
 Compare with INUV
BOSC B.O.S. Better...
NEUTRAL
Mkt Cap
$29M
P/E
9.0
ROE
14.3%
Price
$4.61
 Compare with INUV
MAXN Maxeon Solar...
BEARISH
Mkt Cap
$27M
P/E
0.0
ROE
-%
Price
$1.59
 Compare with INUV
ORIO Orion Digital Corp.
BEARISH
Mkt Cap
$26M
P/E
-
ROE
-11.1%
Price
$1.09
 Compare with INUV

Recent Insider Trading

Insider buy and sell transactions from the last 6 months

HOWE RICHARD K
Director
Stock Award
2026-04-01
36,667 shares
RUIZ WALLACE D
Chief Financial Officer
Stock Award
2026-04-01
7,500 shares
HOWE RICHARD K
Director
Stock Award
2026-02-27
41,667 shares
RUIZ WALLACE D
Chief Financial Officer
Stock Award
2026-02-27
10,000 shares
CAMERON GORDON J.
Director
Stock Award
2026-01-08
3,000 shares
BOND JONATHAN
Director
Stock Award
2026-01-08
3,000 shares
LEE KENNETH EWELL
Director
Stock Award
2026-01-08
3,000 shares
BUCHNER ROBERT C.
Chief Operating Officer
Stock Award
2026-01-08
3,000 shares
HOWE RICHARD K
Chief Executive Officer
Stock Award
2025-12-11
46,002 shares
RUIZ WALLACE D
Chief Financial Officer
Stock Award
2025-12-11
14,100 shares
Insider transactions can signal confidence or concerns about company prospects

SEC Filings

Recent regulatory filings from the SEC EDGAR database

8-K
FORM 8-K
2026-04-03

Inuvia Therapeutics filed an 8-K on April 3, 2026, likely to announce its first-quarter financial results or a corporate update.

10-K
FORM 10-K
2026-03-05

INUV filed its annual 10-K report on March 5, 2026, which includes sections on business operations, risk factors, and management's discussion and analysis. Specific financial highlights and risk details were not provided in the available excerpts.

8-K
FORM 8-K
2026-03-05
8-K
FORM 8-K
2026-02-17
8-K
FORM 8-K
2026-02-02

Inuvia Therapeutics filed an 8-K on February 2, 2026, likely to report its year-end financial results or a material corporate development.

8-K
FORM 8-K
2026-01-29

Inuvia Therapeutics filed a current report on January 29, 2026, likely disclosing fourth-quarter or full-year financial results.

8-K
FORM 8-K
2026-01-28

Inuvia Therapeutics filed a current report likely announcing its fourth-quarter and full-year financial results.

8-K
FORM 8-K
2026-01-15
8-K
FORM 8-K
2025-12-16
10-Q
FORM 10-Q
2025-11-06

INUV filed its Form 10-Q on November 6, 2025. While the filing includes a section dedicated to risk factors, no specific financial highlights or detailed risk descriptions were provided in the available excerpt.

8-K
FORM 8-K
2025-11-06
8-K
FORM 8-K
2025-10-21
8-K
FORM 8-K
2025-10-01
10-Q
FORM 10-Q
2025-08-07
8-K
FORM 8-K
2025-08-07
Data sourced from SEC EDGAR. AI summaries generated automatically.

Wall Street Analysts

Professional analyst ratings and price targets

Consensus
NONE
5 analysts
HC Wainwright & Co.
2026-03-09
reit
Buy Buy
Freedom Broker
2026-02-10
init
Buy
HC Wainwright & Co.
2026-01-29
Maintains
Buy Buy
HC Wainwright & Co.
2025-11-10
Maintains
Buy Buy

Past News Coverage

Recent headlines mentioning INUV from our newsroom.

Newest → oldest
Back to All Stocks
TradingGPT V2 Copilot
Fundamentals • Valuation • Risk
Hi! I'm your fundamentals copilot.

Ask me to:
• Summarize the business quality
• Review valuation and multiples
• Highlight risks and red flags
• Explain growth and margin trends
Features Terminal AI Assistant Analysis Market News Pricing
Start Trading with AI Already have an account? Sign In
Home
Terminal
AI Chat
Markets
Profile